Effect of GLP-1 agonists on testosterone levels: a systematic review and meta-analysis
Abstract
Introduction: Testosterone plays a central role in endocrine and metabolic functions. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), widely prescribed for type 2 diabetes and obesity, have been proposed to modulate testosterone levels. Although this association is not yet covered by clinical guidelines, emerging studies suggest favorable effects, possibly due to weight loss and improved insulin sensitivity. This systematic review and meta-analysis aim to synthesize current evidence on how GLP-1 RAs influence testosterone levels and highlight areas for future investigation.
Materials and methods: A systematic search was conducted using Embase, PubMed, Scopus, Cochrane, and Google Scholar databases through December 2024. Eligible studies included RCTs, cohort studies, and retrospective analyses comparing testosterone levels before and after GLP-1 RA administration. Primary and secondary outcomes included total, free, and bioavailable testosterone, SHBG, and HbA1c. All included studies reported baseline hormone values and used validated measurement techniques. Data analysis was performed using RStudio.
Results: Four studies comprising 219 patients pre-treatment and 216 post-treatment were included. GLP-1 RA use was significantly associated with increased bioavailable testosterone (MD -57.18; 95% CI -87.60 to -26.76; p 2 = 86%) and decreased HbA1c (MD 0.79; 95% CI 0.58 to 1.00; p 2 = 0%). Free testosterone (MD -1.62; p = 0.051) and SHBG (MD -6.62; p = 0.120) showed no…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 219 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.